| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $1.8M | -66.1% |
| SG&A Expense | $6.3M | -28.1% |
| Operating Income | -$8.1M | +42.7% |
| Net Income | -$8.0M | +43.5% |
| EPS (Basic) | -$5.32 | -511.5% |
| EPS (Diluted) | -$5.32 | -511.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Accounts Receivable | $48K | -5.3% |
| Total Assets | $7.7M | +99.3% |
| Current Liabilities | $2.4M | -25.3% |
| Total Liabilities | $2.4M | -25.3% |
| Stockholders' Equity | $5.3M | +756.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$6.8M | +34.6% |
| Financing Cash Flow | $10.6M | +60.8% |